ID: ALA4444300

Max Phase: Preclinical

Molecular Formula: C27H27N3O7

Molecular Weight: 505.53

Molecule Type: Unknown

Representations

Canonical SMILES:  COC(=O)c1cc2cc(NC(=O)CCCOc3cc4c(cc3OC)C(=O)N3CCC[C@H]3C=N4)ccc2o1

Standard InChI:  InChI=1S/C27H27N3O7/c1-34-22-13-19-20(28-15-18-5-3-9-30(18)26(19)32)14-23(22)36-10-4-6-25(31)29-17-7-8-21-16(11-17)12-24(37-21)27(33)35-2/h7-8,11-15,18H,3-6,9-10H2,1-2H3,(H,29,31)/t18-/m0/s1

Standard InChI Key:  OTTJHWIMFFCZRQ-SFHVURJKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 505.53

Molecular Weight (Monoisotopic): 505.1849

AlogP: 4.35

#Rotatable Bonds: 8

Polar Surface Area: 119.67

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.91

CX Basic pKa: 4.06

CX LogP: 2.60

CX LogD: 2.60

Aromatic Rings: 3

Heavy Atoms: 37

QED Weighted: 0.36

Np Likeness Score: -0.51

References

1. Corcoran DB, Lewis T, Nahar KS, Jamshidi S, Fegan C, Pepper C, Thurston DE, Rahman KM..  (2019)  Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF-κB Inhibitory Capacity of Pyrrolobenzodiazepines (PBDs).,  62  (4): [PMID:30688457] [10.1021/acs.jmedchem.8b01849]

Source

Source(1):

• Scientific Literature